Muscone Ameliorates Ovariectomy-Induced Bone Loss and Receptor Activator of Nuclear Factor-κb Ligand-Induced Osteoclastogenesis by Suppressing TNF Receptor-Associated Factor 6-Mediated Signaling Pathways.
RANK
TRAF6
muscone
osteoclasts
postmenopausal osteoporosis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
11
2019
accepted:
09
03
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Postmenopausal osteoporosis is caused by the deficiency of estrogen, which breaks bone homeostasis and induces levels of pro-inflammatory cytokines. Muscone is a potent anti-inflammatory agent and is used to treat bone fracture in traditional Chinese medicine. However, its anti-osteoclastogenic effects remain unclear. For
Identifiants
pubmed: 32265718
doi: 10.3389/fphar.2020.00348
pmc: PMC7099619
doi:
Types de publication
Journal Article
Langues
eng
Pagination
348Informations de copyright
Copyright © 2020 Zhai, Yan, Zhao, Chen, Yang, Cai, He, Huang, Li, Yang, Zhou, Zhao, Wei, Bai and Li.
Références
Circ Res. 2005 Sep 2;97(5):415-7
pubmed: 16100041
Int Immunopharmacol. 2018 Dec;65:348-359
pubmed: 30366278
Biochem Pharmacol. 2010 Aug 1;80(3):352-61
pubmed: 20412788
FASEB J. 2018 Jul;32(7):3487-3501
pubmed: 29394106
Cell Death Dis. 2017 Sep 7;8(9):e3037
pubmed: 28880271
Phytomedicine. 2018 Mar 15;42:43-50
pubmed: 29655696
Nat Commun. 2017 Jan 19;8:13700
pubmed: 28102206
Nat Med. 2011 Sep 11;17(10):1231-4
pubmed: 21909105
Chemistry. 2016 Jun 6;22(24):8137-51
pubmed: 27149882
FASEB J. 2019 Feb;33(2):2574-2586
pubmed: 30285579
Front Pharmacol. 2018 Sep 13;9:1046
pubmed: 30271347
Med Sci Monit. 2018 Dec 08;24:8870-8877
pubmed: 30531686
J Microencapsul. 2019 Jun;36(4):338-355
pubmed: 31190594
Bone Res. 2018 Dec 7;6:36
pubmed: 30534458
Cell Physiol Biochem. 2018;51(6):2858-2871
pubmed: 30562759
J Cell Physiol. 2019 Jul;234(7):11969-11975
pubmed: 30515780
Bone Res. 2018 Nov 27;6:34
pubmed: 30510839
J Bone Miner Res. 2011 Mar;26(3):644-56
pubmed: 20814972
PLoS One. 2014 May 13;9(5):e97123
pubmed: 24824427
Arch Osteoporos. 2018 Nov 7;13(1):121
pubmed: 30406425
Int J Mol Sci. 2019 Jun 18;20(12):
pubmed: 31216684
Cell Death Dis. 2014 Oct 30;5:e1499
pubmed: 25356868
Int J Mol Med. 2014 Jul;34(1):103-11
pubmed: 24807380
Cell Death Dis. 2016 Aug 11;7(8):e2335
pubmed: 27512956
J Immunol. 2018 Jan 15;200(2):749-757
pubmed: 29246953
Bone Res. 2018 Nov 27;6:35
pubmed: 30510840
Prostate. 2009 May 1;69(6):652-61
pubmed: 19152406
Int J Mol Med. 2016 Dec;38(6):1661-1672
pubmed: 27840967
Nat Rev Genet. 2003 Aug;4(8):638-49
pubmed: 12897775
J Mol Med (Berl). 2017 Oct;95(10):1065-1076
pubmed: 28674855
J Cell Physiol. 2019 Dec;234(12):23719-23735
pubmed: 31225646
Endocrine. 2015 Sep;50(1):12-26
pubmed: 25931412
J Clin Med. 2018 Jun 15;7(6):
pubmed: 29914109
Biomed Pharmacother. 2018 Jan;97:825-832
pubmed: 29136757
Inflammopharmacology. 2019 Jun;27(3):503-509
pubmed: 30343452
J Bone Miner Res. 2009 Aug;24(8):1469-80
pubmed: 19292614
J Nat Prod. 2018 Jun 22;81(6):1343-1356
pubmed: 29869503
J Cell Physiol. 2019 May;234(5):6477-6488
pubmed: 30341897
ACR Open Rheumatol. 2019 Aug 03;1(6):382-393
pubmed: 31777818
Bone. 2017 Oct;103:102-115
pubmed: 28666971
EMBO J. 2005 Feb 23;24(4):790-9
pubmed: 15678102
Int J Biol Sci. 2012;8(10):1398-407
pubmed: 23139637
Mediators Inflamm. 2015;2015:597512
pubmed: 26347587